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Summary
 
Activated vascular endothelial cells (ECs) express major histocompatibility complex (MHC)
class II molecules in vitro and in vivo in acute and chronic allograft rejection. However, hu-
man ECs may be limited in their ability to effectively activate CD4
 
1
 
 T cells, because they do
not express members of the B7 family (CD80 and CD86) of costimulatory molecules. In this
study, we show that ECs promote the full activation of CD4
 
1
 
 T cells via trans-costimulatory
interactions. By reverse transcriptase polymerase chain reaction, Western blot, and FACS
 
®
 
analysis, we could not detect the expression of CD80 and CD86 on activated ECs and found
minimal expression on purified CD4
 
1
 
 T cells. In contrast, both CD80 and CD86 were ex-
pressed in allogeneic CD4
 
1
 
 T cell–EC cocultures. Expression of CD86 peaked at early times
between 12 and 24 h after coculture, whereas CD80 was not expressed until 72 h. Addition of
anti-CD86 but not anti-CD80 monoclonal antibodies to cocultures inhibited IL-2 production
and the proliferation of CD4
 
1
 
 T cells to allogeneic donor human umbilical vein ECs (HU-
VECs), as well as to skin and lung microvascular ECs. Furthermore, we found that interferon
 
g
 
–activated ECs but not untreated ECs induced mRNA and cell surface expression of CD80
and CD86 on CD4
 
1
 
 T cells, and these T cells were functional to provide a trans-costimulatory
signal to autologous CD4
 
1
 
 T cells. Blockade of MHC class II and lymphocyte function–associ-
ated antigen 3 but not other EC cell surface molecules on IFN-
 
g
 
–activated ECs inhibited the
induction of CD86 on CD4
 
1
 
 T cells. Transmigration of purified populations of monocytes
across EC monolayers similarly resulted in the induction of functional CD86, but also induced
the de novo expression of the cytokines interleukin (IL)-1
 
a
 
 and IL-12. In addition, EC-modi-
fied monocytes supported enhanced proliferation of allogeneic and autologous CD4
 
1
 
 T cells.
Taken together, these data define the ability of the endothelium to modify CD4
 
1
 
 T cells and
monocytes for trans-costimulatory events. This unique function of the endothelium in alloim-
mune T cell activation has functional consequences for the direct and the indirect pathways of
allorecognition.
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ecognition of alloantigen (donor major or minor his-
tocompatibility antigens) by CD4
 
1
 
 T cells is the ini-
tiating event that ultimately leads to graft rejection. Recip-
ient CD4
 
1
 
 T cells may recognize either intact allo-MHC
class II molecules on donor cells (known as direct allorec-
ognition) or peptides derived from allo-MHC molecules,
shed from the allograft and subsequently processed and pre-
sented bound to MHC class II on recipient APCs (known
as indirect allorecognition) (1). Irrespective of the pathway
of allorecognition, full activation of naive or previously ac-
tivated CD4
 
1
 
 T cells requires a second signal that may be
provided by soluble factors such as cytokines, but more of-
ten is provided by cell surface costimulatory molecules such
as B7-1 (CD80) and B7-2 (CD86) (2, 3). These molecules
are expressed by professional APCs and bind the counter-
receptors CD28 and cytolytic T lymphocyte–associated an-
tigen (CTLA)4
 
1
 
 expressed by CD4
 
1
 
 T cells. Ligation of
 
1
 
Abbreviations used in this paper:
 
 CHO, Chinese hamster ovary; CTLA4,
cytolytic T lymphocyte–associated antigen 4; EC, endothelial cell; HU-
VEC, human umbilical vein EC; ICAM-1, intercellular adhesion mole-
cule 1; LFA-3, lymphocyte function–associated antigen 3; U, abbitor units. 
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CD28 is necessary for maximal CD4
 
1
 
 T cell cytokine pro-
duction, proliferation, and prevention of activation-
induced apoptosis (4, 5). In contrast, ligation of CTLA4
delivers a negative signal to CD4
 
1
 
 T cells (6).
It is well established that activated endothelial cells (ECs)
express class II MHC molecules in vitro and in vivo in re-
jecting allografts, and may therefore provide antigen-
dependent signals to CD4
 
1
 
 T cells for direct activation (7–
11). An unresolved issue is whether ECs can provide the
costimulatory signals required to fully activate CD4
 
1
 
 T
cells (12–16). Current evidence suggesting a role for ECs in
CD4
 
1
 
 T cell activation in vivo is based heavily on in vitro
studies, and only a few studies have provided indirect evi-
dence in vivo (17, 18). The majority of in vitro studies
show that class II–expressing ECs can induce IL-2 produc-
tion and alloproliferation of bulk populations of CD4
 
1
 
 T
cells, an effect largely dependent on costimulation by en-
dothelial lymphocyte function–associated antigen (LFA)-3
(12–15). However, inhibition of CD2–LFA-3 interactions
with anti–LFA-3 mAbs only partially inhibits EC-induced
CD4
 
1
 
 T cell cytokine production and alloproliferation,
suggesting a role for other costimulatory molecules in this
process. Although B7-dependent costimulation has been
demonstrated in allogeneic mouse EC-induced T cell acti-
vation (19) and xenogenic pig EC-induced human T cell
activation (20, 21), firm conclusions have not been made as
to whether CD28–B7 interactions are functional in the ac-
tivation of human CD4
 
1
 
 T cells by human ECs. This issue
is relevant for a proactive role of ECs in rejection, because
activation of naive CD4
 
1
 
 T cells (induction of primary im-
mune responses) and the activation of previously activated
CD4
 
1
 
 T cells is dependent on CD28-mediated costimula-
tion (22, 23). Indeed, in the absence of CD28-mediated
signals, naive CD4
 
1
 
 T cells may be rendered refractory to
further stimulation by antigen (clonal anergy) (24), or reac-
tivation responses may be qualitatively different (25). Fur-
thermore, recent studies have demonstrated a requirement
for B7 costimulation at the local site of inflammation (26).
In these studies we investigate the role of CD28–B7 inter-
actions in human EC-induced CD4
 
1
 
 T cell alloactivation.
Our data provide new insight into the ability of ECs to
modify leukocytes to promote direct (and perhaps indirect)
allorecognition and define novel mechanisms by which al-
lograft ECs may promote transplant rejection.
 
Materials and Methods
 
Reagents and Antibodies.
 
Antibodies used in these studies in-
clude seven anti-CD86 mAbs; IT2.2 and FUN-1 clone (Phar-
Mingen), anti–human CD86 (Serotec), anti–human CD86 (B7-F3,
gift from P. Linsley, Bristol Myers Squibb, Princeton, NJ), HF2
3D1, HA5 2B7, HA3 1F9 (gifts from V.J. Kuchroo, Brigham and
Women’s Hospital, Boston, MA), anti–human CD80 (PharMin-
gen), anti–human CD25 (PharMingen, San Diego, CA); anti–
human LFA-3 (IE6, gift from P. Hochman, Biogen Inc., Cam-
bridge, MA), anti–human CD40 (220; a gift from D. Hollenbaugh,
Bristol Myers Squibb), anti–human OX40 (Ancell Corp.), anti–
human intercellular adhesion molecule (ICAM)-1 (RR1/1, a gift
 
from T.A. Springer, Center for Blood Research, Harvard Medical
School, Boston, MA), anti–HLA-DR (LB3.1, a gift from A.H.
Lichtman, Brigham and Women’s Hospital), and negative con-
trol mouse IgG (K16/16, a gift of M. Gimbrone, Brigham and
Women’s Hospital). Human CTLA4 Ig and control fusion pro-
tein were gifts from Dr. Peter Linsley (Bristol Myers Squibb).
Cytokines used were recombinant human IFN-
 
g
 
 (Genzyme) and
TNF-
 
a
 
 (a gift from Biogen Inc.). Other reagents used included
recombinant soluble CD154 (a gift from D. Hollenbaugh), LPS
(Sigma Chemical Co.), and PHA (Sigma Chemical Co).
 
Cell Isolation and Culture.
 
Endothelial cells were isolated from
human umbilical cords as previously described (27) and were
grown in M199 medium (BioWhittaker) containing 10% FCS
(GIBCO BRL), EC growth supplement, 1% penicillin/strepto-
mycin, 
 
l
 
-glutamine, and heparin. Cultured cells were harvested
in trypsin/ethylenediaminetetraacetic acid (Sigma Chemical Co.)
and subcultured for use at passages 2–4. Saphenous vein ECs
were a gift from Dr. P. Libby (Brigham and Women’s Hospital)
(28). Single donor, dermal, and lung microvascular ECs were
purchased from Clonetics.
Cell membrane fractions of ECs or CD4
 
1
 
 T cells were pre-
pared as previously described (29). In brief, untreated or IFN-
 
g
 
–
treated ECs (2–4 
 
3
 
 10
 
6
 
) were harvested by gentle scraping,
washed, and resuspended in lysis buffer containing 0.25 M su-
crose, 10 mM Tris (pH 7.4), 10 mM NaCl, 0.1 M MgCl
 
2
 
, and
1 mM PMSF. The cells were lysed by homogenization and were
centrifuged at 1,000 
 
g
 
 for 15 min. Supernatants were centrifuged
at 100,000 
 
g
 
 for a further 30 min. All manipulations were per-
formed at 4
 
8
 
C. Pellets were resuspended in RPMI and added di-
rectly to CD4
 
1
 
 T cells (10
 
6
 
) in 96-well plates. For select experi-
ments, cell membranes were prepared from unactivated or
mitogen-activated CD4
 
1
 
 T cells (10
 
7
 
 cells/condition).
PBMCs were isolated by Ficoll-Hypaque gradient centrifuga-
tion from blood obtained from healthy volunteers. CD4
 
1
 
 T cells
were isolated from PBMCs by positive selection using anti-CD4–
coated magnetic beads (Dynal Inc.) according to the manufac-
turer’s instructions. Magnetic beads were subsequently removed
using Detachabead (Dynal Inc.). In some experiments CD4
 
1
 
 T
cells were further purified by negative depletion of CD14 and
HLA-DR expressing cells using a CD14-coated microbead col-
umn (MiniMACS separation column; Miltenyi Biotec) and pan-
ning on anti–HLA-DR (LB3.1) coated plastic culture dish re-
spectively. The purity of the CD4
 
1
 
 T cells using these methods
was 98 and 99.7%, respectively. Purity was assessed by double
stain FACS
 
®
 
 analysis for CD3 and CD4 cell surface markers. Pu-
rified cells were unactivated as assessed by the lack of spontaneous
proliferation, IL-2 and IFN-
 
g
 
 production, and CD25 cell surface
expression, as previously described (30). Human monocytes were
isolated from platelet pheresis residues by centrifugation on den-
sity gradients (LSM; Organon Teknika), followed by counterflow
centrifugation elutriation (31). Monocytes isolated by this tech-
nique are 
 
.
 
90% pure and are relatively unactivated as deter-
mined by minimal alterations in cell surface activation markers. In
some experiments, monocytes were isolated from PBMCs by posi-
tive selection using CD14-coated microbeads (MiniMACS separa-
tion column; Miltenyi Biotec).
CD80-, CD86-, and neomycin-transfected Chinese hamster
ovary (CHO) cells (a gift from Dr. G. Freeman, Dana Farber
Cancer Institute, Boston, MA) were cultured in collagen-coated
tissue culture flasks in complete RPMI with 10% FCS. Cells were
harvested by trypsinization and fixed in 0.4% PFA before addi-
tion to EC–CD4
 
1
 
 T cell cocultures.
 
CD4
 
1
 
 T cell–EC Coculture.
 
Primary cultures of ECs (passages 
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3–4) were treated with IFN-
 
g
 
 (1,000 U/ml) for 72 h to upregu-
late class II MHC. IFN-
 
g
 
–treated ECs (5 
 
3
 
 10
 
4
 
/well) were then
irradiated (1,750 rads) and cocultured with resting CD4
 
1
 
 T cells
(5 
 
3
 
 10
 
5
 
/well) in 96-well cell culture plates in a final volume of
200 
 
m
 
l. Additional cells or reagents were added as indicated.
Coculture supernatants were taken at days 3 and 5 for cytokine
analysis by specific ELISA. Proliferation was assessed after 6 d by
[
 
3
 
H]thymidine incorporation for the last 18 h of coculture. Cells
were harvested by an automated cell harvester and incorporated
radioactivity was assessed by a Beckman Betamax counter.
In separate experiments, we examined whether ECs modify
CD4
 
1
 
 T cells to express functional CD86. CD4
 
1
 
 T cells were
cultured on IFN-
 
g
 
–treated human umbilical vein EC (HUVEC)
monolayers for 24–72 h and then reisolated by positive selection
using CD4-coated magnetic beads (Dynal Inc.). These cells were
termed “EC-modified” CD4
 
1
 
 T cells. EC-modified CD4
 
1
 
 T
cells (10
 
5
 
) were irradiated (1,750 rads) and cocultured with rest-
ing autologous CD4
 
1
 
 T cells (5 
 
3
 
 10
 
5
 
) in the presence of submi-
togenic doses of PHA (0.3 
 
m
 
g/ml). Coculture supernatants were
taken at 24 h for specific ELISA. Proliferation was assessed after 3 d
of coculture as described above.
 
Transmigration Assay.
 
Transmigration assays were per-
formed using a protocol modified, as follows, from one described
previously (32). HUVECs were seeded at 2 
 
3
 
 10
 
5
 
 cells/cm
 
2
 
 on
collagen-coated, 8-
 
m
 
m-pore size polycarbonate tissue culture
Transwell inserts (Costar Corp.) and were cultured for 5 d to at-
tain  confluence. Confluency was assessed by exclusion of
FITC-labeled dextran in control wells as previously described
(32). HUVECs were pretreated with IFN-
 
g
 
 (1,000 U/ml) for 72
h to upregulate MHC class II. Purified, resting monocytes (5 
 
3
 
10
 
6
 
) were added onto the transwell and allowed to transmigrate
across untreated or IFN-
 
g
 
–treated ECs. HUVECs were washed
thoroughly to remove IFN-
 
g
 
 before addition of monocytes.
Transmigrated cells were counted and RNA was isolated from 2
 
3
 
 10
 
6
 
 cells 12 h after transmigration. Induction of monocyte
CD86 and cytokine mRNA expression was determined by semi-
quantitative reverse transcriptase (RT)-PCR and RNase protec-
tion assay.
 
Isolation of RNA and RT-PCR Analysis.
 
Total RNA was
prepared using the Ultraspec RNA isolation system (Biotecx) ac-
cording to the manufacturer’s instructions, and was quantified by
spectrophotometry. cDNA was prepared by reverse transcription
of 5 
 
m
 
g of RNA using random hexamer primers (100 ng/
 
m
 
l) and
Moloney murine leukemia virus reverse transcriptase (50 
 
m
 
m/
 
m
 
l)
(Stratagene) in a 50-
 
m
 
l reaction. 10 
 
m
 
l of cDNA was used for
each PCR amplification reaction. PCR was performed with Taq
DNA polymerase using the buffer supplied by the manufacturer
(Boehringer Mannheim). The PCR primers were: human CD80,
sense: 5
 
9
 
-CAT CAC GGA GGG TCT TCT AC-3
 
9
 
 and anti-
sense: 5
 
9
 
-AGG ATC TTG GGA AAC TGT TGT-3
 
9
 
; and hu-
man anti-CD86, sense: 5
 
9
 
-AGG ACA AGG GCT TGT ATC
AA-3
 
9
 
 and antisense: 5
 
9
 
-ATT GCT CGT AAC ATC AGG GA-
3
 
9
 
. The PCR conditions were 94
 
8
 
C for 1 min, 60
 
8
 
C for 1 min,
and 72
 
8
 
C for 2 min for 35 cycles. PCR products were analyzed
by ethidium bromide staining in 1.5% agarose gels using standard
techniques.
 
RNase Protection Assays.
 
RNase protection was performed
using the Riboquant™ Multi-Probe RNase Protection assay sys-
tem (PharMingen). RNA was isolated as described above. 
 
32
 
P-
labeled probes were synthesized from the hCK-2 human cyto-
kine multi-probe template set and were hybridized overnight with
RNA samples in hybridization buffer according to the manufac-
turer’s instructions. Samples were digested with RNase and T1
 
mix in RNase buffer and protected probes were purified and
were run on a 5% acrylamide gel in 0.5% TBE buffer. Human
control RNA and a dilution of the probe set (serving as size
markers) were run in parallel. The gel was absorbed onto filter
paper, dried, and exposed onto Kodak photographic paper at
2708C for 24 h.
Cytokine Assays. IL-2 was assessed by specific ELISA. Pri-
mary and secondary antibodies were purchased from Genzyme
and were used according to the recommended protocol. In brief,
96-well flat-bottomed ELISA plates (Falcon; Becton Dickinson
Labware) were coated with primary antibody overnight at 48C.
Blocking was then performed with 4% BSA in PBS for 2 h at
378C and neat coculture supernatants or standards were added to
each well in duplicate for 1 h at 378C. After the incubation, sec-
ondary biotinylated anti–IL-2 mAb was added and the ELISA
was developed using avidin alkaline phosphatase (Sigma Chemi-
cal Co.) and phosphatase substrate (Sigma Chemical Co.). In be-
tween each step, the plates were washed in PBS with 0.01% Tri-
ton X-100. Plates were read at 405 nm in an E-Max ELISA plate
reader (Molecular Devices).
Flow Cytometry. Cell suspensions of CD41 T cells, ECs, or
monocytes were analyzed by direct immunofluorescence. In
brief, 1–2 3 106 cells were incubated with FITC- and/or PE-
conjugated mAbs at 48C for 30 min and were fixed in 1% PFA.
Stained cells were then analyzed by FACScan® (Becton Dickin-
son). Monocytes were preincubated with buffer containing 20%
non-A non-B human serum before flow cytometry to block non-
specific Fc receptor binding and optimize specific binding.
Western Blotting. Western blot was performed on z5 3 106
cells per condition. Cells were lysed in PBS containing 1% NP-40,
and protease-inhibitor (Boehringer Mannheim) and lysates were
separated by standard 10% SDS-PAGE and transferred onto poly-
vinylidene difluoride membranes. Blots were blocked overnight
at 48C in Tris-buffered saline containing 0.1% Tween 20 and 2%
BSA before incubation with optimal concentrations of primary
antibody diluted in TBS/0.1% Tween 20 for 12 h at 48C. After
four washes in TBS/0.1% Tween 20, blots were incubated in
peroxide-conjugated goat anti–mouse secondary antibody (Jack-
son ImmunoResearch Labs.) at a 1:2,500 dilution in TBS for 4 h
at 48C. The blots were then washed and developed by chemilu-
minescence (Amersham Inc.).
Results
Expression of CD80 and CD86 in CD41 T Cell–EC Co-
cultures. To investigate a role for CD80 and CD86 in
CD41 T cell–EC interactions, we initially examined the
expression of these molecules by resting or activated CD41
T cells, and ECs alone or after coculture of both cell types
(Fig. 1). Our findings were that TNF-a, IFN-g, IL-1, or
soluble CD40 ligand (CD40L)–stimulated HUVECs do
not express CD80 or CD86 mRNA by RT-PCR; likewise
resting CD41 T cells do not express CD80 and express
variable and low levels of CD86 mRNA. In contrast, we
found a marked expression of both CD80 and CD86
mRNA in CD41 T cell–HUVEC cocultures. CD86
mRNA was detected as early as 6 h and was maximal by 72 h
of coculture, whereas CD80 mRNA was only expressed in
cells harvested at 72 h of coculture (Fig. 1 A). CD86 pro-
tein was detected by Western blot in 72-h CD41 T cell–
HUVEC cocultures but not in resting CD41 T cells or558 ECs Modify the Costimulatory Capacity of Transmigrating Leukocytes
TNF-a, IFN-g, or soluble CD40 ligand–activated HU-
VECs (Fig. 1 B). By FACS® analysis, anti-CD80 mAbs,
seven anti-CD86 mAbs, and CTLA4 Ig did not bind to
resting or cytokine-activated HUVECs, saphenous vein
ECs, dermal microvascular ECs, or lung microvascular
ECs; although positive control CD80- and CD86-trans-
fected CHO cells consistently demonstrated high levels of
binding (Fig. 1 C and data not shown). Thus, human ECs
express neither CD80 nor CD86, but both these molecules
are induced in CD41 T cell–EC cocultures.
Function of CD86 and CD80 in CD41 T Cell–Allogeneic
EC Cocultures. We next wished to determine the func-
tion of CD86 and CD80 in CD41 T cell–EC interactions.
Purified CD41 T cells were rested for 48 h and were cocul-
tured with either HUVECs, saphenous vein ECs, dermal
microvascular ECs, or lung microvascular ECs, untreated
or treated with IFN-g for 72 h to upregulate class II MHC.
Anti-CD86 mAbs, anti-CD80 mAbs, or control isotype
antibodies were added to cocultures as indicated by each
experiment (Fig. 2). We found that anti-CD86 mAbs con-
sistently inhibited IFN-g–treated HUVEC-induced CD41
T cell alloproliferation (Fig. 2 A). Maximal inhibition with
anti-CD86 mAbs was variable (20–50%) and was less than
that observed by blocking CD2–LFA-3 interactions with
Figure 1. Expression of CD80 and CD86 in allogeneic CD41 T cell–
EC cocultures. (A) Semiquantitative RT-PCR was performed on RNA
samples harvested from resting CD41 T cells, IFN-g–treated HUVECs,
or cocultures of CD41 T cell with IFN-g–treated HUVECs at various
time points. Illustrated is one experiment representative of four. Resting
CD41 T cells occasionally show low level expression of CD86. (B) West-
ern blot analysis of 24-h TNF-a–, soluble CD40 ligand–, and IFN-g–acti-
vated ECs, or CD41 T cells or 72-h CD41 T cell–IFN-g–treated EC
cocultures. Two different anti-CD86 antibodies were used for our stud-
ies: IT2.2 (PharMingen; lanes 1–3) and B7-F3 (Bristol Myers Squibb;
lanes 4–7). Illustrated are two representative blots showing absent CD86
expression on ECs and CD41 T cells, but enhanced expression in CD41–EC
cocultures. Positive controls were CD86-transfected CHO cells. Data is
representative of four experiments. (C) FACS® analysis of untreated
HUVECs or 72-h IFN-g (1,000 U/ml)–treated HUVECs for CD80,
CD86, and HLA-DR (positive control). Control isotype mouse IgG was
used as a negative control. As positive controls, we used anti-CD80 mAb
and anti-CD86 mAbs bound to CD80- and CD86-transfected CHO
cells, respectively (not shown).
Figure 2. Function of CD80 and CD86 in allogeneic CD41 T cell–EC
cocultures. CD41 T cells were cultured alone (white bars), with un-
treated HUVECs (gray bars), or with HUVECs that were treated with
IFN-g (1,000 U/ml) for 72 h (black bars). (A) Anti-CD86 antibody
(IT2.2, clone, 10 mg/ml), LFA-3 (5 mg/ml), or combinations were added
into cocultures of CD41 T cells with IFN-g–treated HUVECs as indi-
cated. Data represents the mean of 10 experiments performed in triplicate
cultures 6 1 SD. (B) Dose–response effect of anti-CD86 antibody (IT2.2
clone) on CD41 T cell alloproliferation. We also find that anti-CD86
mAbs inhibit EC-induced CD41 T cell IL-2 production (data not
shown). Results are representative of four similar experiments performed
in triplicate cultures 6 1 SD. (C) Coculture of CD41 T cells with various
IFN-g–treated microvascular endothelial cells in the absence (black bars)
or presence (gray bars) of anti-CD86 mAbs (10 mg/ml, IT2.2 clone). Re-
sults are representative of two similar experiments performed in triplicate
cultures 6 1 SD (*P , 0.05). (A–C) In all experiments, proliferation was
assessed after 6 d of coculture by [3H]thymidine uptake.559 Denton et al.
anti–LFA-3 mAbs. In addition, we found that the combi-
nation of anti-CD86 and anti–LFA-3 mAbs provided addi-
tive inhibition of CD41 T cell alloproliferation (Fig. 2 A)
and IL-2 production (data not shown). The inhibitory ef-
fects of anti-CD86 mAbs was dose dependent (Fig. 2 B)
and was observed when other types of human ECs were
cocultured with CD41 T cells (Fig. 2 C). In contrast, inter-
ruption of CD28–CD80 interactions using anti-CD80
mAbs did not inhibit EC-induced CD41 T cell alloprolif-
eration, most likely because CD80 is not expressed at early
time points in the CD41 T cell–EC coculture (Fig. 1 A).
Thus, CD86 but not CD80 is functional in allogeneic EC-
induced CD41 T cell activation.
Human ECs Induce CD86 Expression by CD41 T Cells.
Since we find that human ECs do not express CD86, we
next wished to assess CD41 T cell CD86 expression and
function in our model. Previous studies have shown that
activated CD41 T cells may express both CD80 and CD86
(33, 34). CD41 T cells were cultured with IFN-g–treated
HUVECs and CD86 expression determined by double
stained FACS® analysis of cells. As illustrated in Fig. 3 A,
we found low levels of CD86 on resting CD41 T cells, but
augmentation of CD41 T cell CD86 expression after cocul-
ture with IFN-g–treated ECs. Maximal expression of
CD41 T cell CD86 was observed after 72 h of coculture.
We also confirmed that CD86 was induced de novo on
CD41 T cells by sorting and culturing CD862CD41 T
cells with IFN-g–treated ECs for 24 h. Consistently, we
found that ECs induce de novo expression of CD86 on
CD41 T cells.
Furthermore, to determine whether EC-induced CD86
expression by CD41 T cells was dependent on cell contact,
we generated cell membranes from ECs and incubated
them with CD41 T cells. Membrane preparations from
IFN-g–activated ECs but not resting ECs induced CD41
T cell CD86 mRNA expression by RT-PCR, consistent
with the interpretation that induction of CD41 T cell
CD86 is mediated by a cell surface molecule(s) on activated
ECs (Fig. 3 B). However, when membranes generated
from unactivated or activated CD41 T cells were incubated
with ECs, they failed to induce EC expression of CD86. As
a positive control, activated CD41 T cell membranes en-
hanced EC E-selectin expression (Fig. 3 C).
Functionality of EC-induced CD41 T Cell CD86. Having
established that ECs induce CD86 expression on CD41 T
cells, we next assessed function. CD41 T cells were cul-
tured with IFN-g–treated ECs and were reisolated by pos-
itive selection after 24 h of coculture. These EC-modified
CD41 T cells were then irradiated and cocultured either
alone or with resting autologous CD41 T cells in the pres-
ence of submitogenic doses of PHA (0.3 mg/ml). Although
resting CD41 T cells alone and EC-modified CD41 T cells
alone failed to proliferate to low dose PHA, coculture of
both cell types resulted in enhanced proliferation, which
was inhibited by z50–80% by anti-CD86 mAbs (Fig. 4 A).
This suggests that induced CD86 on EC-modified CD41
T cells provides an effective costimulatory signal in trans to
resting CD41 T cells. However, the proliferative responses
of CD41 T cells in this trans-costimulation assay were less
than those induced by ECs (Fig. 2 and data not shown).
We note that this is consistent with the ability of ECs to
provide additional costimulatory signals such as LFA-3–
dependent signals as reported by others (13, 35).
To determine the molecular basis for EC modification of
CD41 T cell costimulatory activity, we incubated CD41 T
cells with IFN-g–treated ECs in the absence or presence of
anti–ICAM-1, anti–LFA-3, anti–HLA-DR mAbs, anti-
CD40 mAbs, anti-OX40 mAbs, or isotype control anti-
bodies for 24 h. EC-modified CD41 T cells were then re-
isolated and irradiated, and were added to resting CD41 T
cells in the presence of submitogenic doses of PHA as de-
scribed above. We found that anti–LFA-3 and anti–HLA-
DR, but not anti-CD40, anti-OX40L, anti–ICAM-1, or
control antibody, inhibited the subsequent CD41 T cell
costimulatory effect (Fig. 4, B and C, and data not shown).
Anti-CD40 antibodies also failed to inhibit T cell–T cell
Figure 3. EC induction of CD86 on CD41 T cells. (A) Double stain
FACS® analysis of resting CD41 T cells, or CD41 T cells that were cul-
tured with IFN-g–activated ECs for 72 h using FITC-conjugated CD3
and PE-conjugated CD86 antibodies (PE-conjugated mouse isotype anti-
body served as control). (B) The expression of CD86 by semiquantitative
RT-PCR on RNA harvested from CD41 T cells alone (lane 1), CD41 T
cells cultured with cell membrane preparations from unactivated ECs
(lane 2), or CD41 T cells cultured with cell membrane preparations from
IFN-g–treated ECs (lane 3). (C) CD86 and E-selectin expression by RT-
PCR on RNA harvested from HUVECs (lane 1), HUVECs cultured
with cell membrane preparations from resting CD41 T cells (lane 2), or
HUVECs cultured with cell membrane preparations from PHA-activated
CD41 T cells (lane 3). IFN-g–treated monocytes were used as a positive
control (lane 4). Membranes were prepared as described in Materials and
Methods from 5 x106 cells. Data is representative of three similar experi-
ments.560 ECs Modify the Costimulatory Capacity of Transmigrating Leukocytes
trans-costimulation (Fig. 4 C). Thus, induction of func-
tional CD86 on CD41 T cells is in part dependent on in-
teractions between CD41 T cells and EC class II MHC and
LFA-3.
Finally, to confirm functionality of CD86-dependent
trans-costimulation for direct allorecognition (when signal
one is provided by alloantigen on ECs rather than mito-
gen), CD41 T cells were cocultured with IFN-g–treated
ECs in the presence of increasing numbers of CHO cells
transfected with CD86. Mock-transfected CHO cells were
used as a negative control. CD86-transfected, but not
mock-transfected, CHO cells enhanced EC-induced
CD41 T cell alloproliferation (Fig. 5 A) and IL-2 produc-
tion (data not shown) in a dose-dependent manner that is
inhibited by anti-CD86 mAbs and CTLA4 Ig (Fig. 5 B).
This data confirms that CD41 T cells can receive CD86
costimulation in trans when signal one is provided by al-
loantigen on ECs.
EC-induced CD86 Trans-costimulation Is Mediated by CD31
CD41 T Cells and Not by Contaminating CD41 Dendritic
Cells. It has been reported that a subpopulation of periph-
eral blood CD41 cells are HLA-DR1 and CD32 myeloid
derived dendritic cells (36). We found that z2% of our
CD41 cells were CD32, and therefore we wished to con-
firm that the CD86-dependent trans-costimulation described
above is indeed due to CD86 expressed by CD41 T cells
and not to dendritic cell CD86. We further purified our
CD41 cells by negative selection for HLA-DR and CD14
expressing cells (as described in Materials and Methods). The
resulting cells were CD41CD31HLA-DR2 T cells (Fig. 6
Figure 4. EC-modified CD41 T cells provide CD86-mediated trans-
costimulation to autologous CD41 T cells. (A) CD41 T cells were cul-
tured on a monolayer of IFN-g–treated endothelial cells for 72 h and
were reisolated from the coculture by positive selection using CD4-
coated magnetic beads. These cells were then irradiated (1,750 rads) and
105 cells were cultured with autologous CD41 T cells (5 3 105) in the
presence of low dose PHA (0.3 mg/ml) for 4 d. Shown are the prolifera-
tive responses of CD41 T cells. Anti-CD86 (10 mg/ml, IT2.2 clone),
anti-CD80 (10 mg/ml, BB1-1 clone), or CTLA4 Ig (10 mg/ml) were
added as indicated. Illustrated is one experiment representative of three
similar experiments in triplicate cultures 6 1 SD. Anti–HLA-DR mAbs
(LB3.1) do not inhibit CD41 T cell proliferation (data not shown). (B
and C) To determine the EC cell surface molecule(s) that mediates induc-
tion of CD41 T cell CD86 expression, anti–HLA-DR (LB3.1), anti–
LFA-3 (1E6), anti–ICAM-1 (RR1/1), anti-CD40(220), or anti-OX40
(Ancell) were added to the primary CD41 T cell–EC coculture at optimal
blocking concentrations. CD41 T cells were reisolated, irradiated, and
added to autologous CD41 T cells in secondary cultures in the presence
of low dose PHA as described above. Proliferation was assessed by
[3H]thymidine incorporation for the final 18 h of a 6-d culture. Data is a
representative of three experiments performed in triplicate cultures 6 1
SD. Irradiated stimulator cells alone failed to proliferate, as illustrated in A.
Figure 5. Effect of CD86 trans-costimulation on alloantigen-induced
CD41 T cell activation. (A) CD41 T cells (5 3 105) were cocultured
with IFN-g–treated endothelial cells in the presence of increasing num-
bers of either CD86-transfected or mock-transfected CHO cells. CHO
cells were fixed in 0.4% paraformaldehyde before coculture to inhibit
spontaneous proliferation. (B) Anti-CD86 (10 mg/ml, IT2.2) or CTLA4
Ig (10 mg/ml) were added to cocultures as indicated. Proliferation was as-
sessed by [3H]thymidine incorporation for the final 18 h of a 6-d culture.
Shown is one experiment representative of four in triplicate cultures 6 1
SD. CD41 T cells cocultured with CHO cells alone did not proliferate.561 Denton et al.
A) and express low levels of CD86. However, consistently
after coculture with IFN-g–treated ECs, these T cells exhibit
augmented CD86 expression (Fig. 6 B). Furthermore, these
T cells provide effective trans-costimulation to autologous T
cells in the presence of low dose mitogen (Fig. 6 C). Trans-
costimulation is mediated in part by CD86 (with 25–75% in-
hibition observed with anti-CD86 mAbs) but also involves
other cell surface molecules including LFA-3 (data not
shown and Fig. 4). There is no antigen-dependent compo-
nent to the T cell–T cell proliferative response, since anti–
HLA-DR antibody (LB3.1) failed to inhibit proliferation
with concentrations of mitogen (PHA . 0.3 mg/ml) used in
our model. However, in the absence of mitogen or at low
doses of mitogen (PHA , 0.1 mg/ml), anti–HLA-DR par-
tially inhibits proliferative responses.
ECs Induce Functional Costimulatory Activity in Transmi-
grating Monocytes. We next wished to determine whether
ECs modify the costimulatory and antigen presenting ca-
pacity of monocytes. Recent studies suggest that transmi-
gration of monocytes across ECs promotes their differentia-
tion into dendritic cells (37, 38). Indeed, a novel function
of ECs may be to enhance the antigen presenting and co-
stimulatory function of infiltrating APCs in the course of
alloimmune inflammatory reactions and rejection. Mono-
cytes were isolated by elutriation in order to obtain a rela-
tively unactivated cell population. Cells were then allowed
to transmigrate across resting or 72-h IFN-g–treated con-
fluent EC monolayers in transwells as described in Materi-
als and Methods. After 12 h, cells were harvested from the
lower chamber of the transwell and RNA was isolated for
analysis by RT-PCR and RNase protection. We found
that transmigration of monocytes across IFN-g–treated
ECs, and to a lesser extent resting ECs, resulted in the in-
duction of monocyte CD86 mRNA expression by RT-
PCR (data not shown) and enhanced CD86 protein ex-
pression by FACS® analysis (Fig. 7 A). Transmigration
Figure 6. EC-induced CD86 trans-
costimulation is mediated by CD31CD41 T
cells and not by contaminating CD41 den-
dritic cells. (A) FACS® analysis of CD41 T
cells purified by positive selection and deple-
tion of HLA-DR1 and CD141 cells. Dou-
ble staining of purified CD41 T cells with
FITC-conjugated CD3 and PE-conjugated
CD4 antibodies. (B) CD31CD41 T cells
were cocultured with IFN-g–treated ECs
for 72 h and were repurified by positive se-
lection. FACS® analysis was then performed
by double staining for CD3 and CD86. His-
tograms show shifts in PE-conjugated CD86
(shaded area) and control PE-isotype anti-
body staining by CD31 cells gated within
regions R1 (scattergram in A). Illustrated are
CD86 expression in resting, 72-h EC-acti-
vated and PHA (1 mg/ml)-activated CD41
T cells. (C) CD41 T cells were modified by
ECs to express CD86 (as above) and were
irradiated and cocultured with resting autol-
ogous CD41 T cells in the presence of low
dose mitogen (PHA 0.3 mg/ml). Anti-
CD86 (10 mg/ml) was added to cultures as
described in Fig. 4. Shown is one experi-
ment representative of four performed in
triplicate cultures 6 1 SD. Irradiated stimu-
lator cells alone failed to proliferate.562 ECs Modify the Costimulatory Capacity of Transmigrating Leukocytes
across transwell inserts not coated with ECs did not result
in induction of CD86 (data not shown). We also found that
transmigration of monocytes across IFN-g–treated ECs re-
sulted in the expression of the cytokine IL-1a as deter-
mined by RNase protection assay (Fig. 7 B); and coincuba-
tion of monocytes with IFN-g–treated ECs resulted in
induction of monocyte IL-12 expression (Fig. 7 C).
Finally, we compared the ability of resting monocytes
with that of EC-modified monocytes to activate allogeneic
and autologous CD41 T cells. After a 72 h coculture with
IFN-g–treated ECs, CD141 monocytes were reisolated by
positive selection and cultured with allogeneic or autolo-
gous CD41 T cells at fixed responder/stimulator ratios. We
found that EC-modified monocytes consistently induced
greater proliferation of allogeneic CD41 T cells than did
resting monocytes (Fig. 8 A), an effect inhibited by CTLA4
Ig and anti–HLA-DR antibodies (Fig. 8 B). CTLA4 Ig
caused a greater percentage of inhibition of CD41 T cell
proliferation induced by EC-modified monocytes, consis-
tent with enhanced expression of CD86 by these cells.
Thus, ECs augment the capacity of monocytes to provide
costimulatory signals to CD41 T cells activated by direct
allorecognition. Furthermore, EC-modified monocytes in-
duced proliferation of autologous CD41 T cells. This sug-
gests that ECs may donate alloantigen to monocytes for
presentation to autologous CD41 T cells via the indirect
pathway of allorecognition.
Discussion
Microvascular ECs express cell surface molecules that
mediate both the recruitment into and the activation of
leukocytes within vascularized solid organ transplants.
Thus, it is proposed that interactions between CD41 T
cells and microvascular graft ECs are critical for rejection
(12). Antigen-dependent activation of CD41 T cells is ini-
tiated by interactions between the TCR and foreign pep-
tide in association with MHC class II molecules. ECs ex-
press MHC class I and class II molecules and provide
antigen-dependent signals to T cells in vitro (7–12) and in
vivo (17, 18). However, the ability of human endothelium
to provide effective costimulatory signals for full CD41 T
cell activation is more controversial (12–16). Surprisingly,
only endothelial LFA-3 has been identified to possess co-
stimulatory function with little if any contribution of other
human EC cell surface molecules. Endothelial LFA-3 inter-
acts with T cell CD2 and initiates a series of activation re-
sponses in CD41 T cells that result in IL-2, IL-4, and IFN-g
production (10, 15, 39). Since naive and previously acti-
vated CD41 T cells are dependent on CD28 signaling for
effective activation (22), we wished to examine in more
detail the role of CD28–B7 interactions in EC-induced
CD41 T cell activation. Our results provide insight into
how graft ECs may modify infiltrating leukocytes for pro-
vision of CD28-mediated costimulation in trans and pro-
mote CD41 T cell activation via direct and indirect al-
lorecognition.
In these studies, we confirm that human ECs do not ex-
press CD80 or CD86 mRNA, nor protein assessed by RT-
PCR, Western blotting, and FACS® analysis, respectively.
However, we do find that CD86 is induced and is func-
tional in CD41 T cell–EC interactions due to its expression
on CD41 T cells and the ability of these cells to deliver
CD86 mediated costimulatory signals in trans. Indeed, we
demonstrate induction of expression of CD86 on CD41 T
cells after coculture with ECs. Blockade of CD41 T cell
CD86 using several anti-CD86 mAbs caused a variable but
Figure 7. Transmigrated monocytes express enhanced costimulatory
molecules. Purified populations of monocytes (107) were cultured with
IFN-g–treated HUVEC monolayers in the upper chamber of a 8-mm-
pore polycarbonate transwell. (A) Monocyte CD86 protein expression
was determined by FACS® 24 h after transmigration. Illustrated is the
FACS® analysis of CD86 in resting monocytes and transmigrated mono-
cytes. Isotype control PE antibody served as control. Representative anal-
ysis of three experiments. (B) Monocytes were harvested from the lower
chamber after 12 h. Illustrated is the expression of IL-1a by RNase pro-
tection from resting, transmigrated monocytes and positive control IFN-
g–activated monocytes. (C) RNA was harvested from cocultures of
monocytes and IFN-g–activated endothelial cells. Illustrated is the ex-
pression of IL-12 by RNase protection in resting monocytes, monocytes
cocultured with IFN-g–activated ECs, and LPS (1 mg/ml)-stimulated
monocytes. Unactivated or IFN-g–activated ECs do not express IL-12,
and IFN-g alone only weakly induces IL-12 expression in resting mono-
cytes (not shown).563 Denton et al.
consistent inhibition of CD41 T cell proliferation and IL-2
production when alloantigen was presented to CD41 T
cells by several different human microvascular ECs. Fur-
thermore, combined blockade of LFA-3 and CD86 results
in additive inhibition of CD41 T cell activation, suggesting
that these molecules participate in parallel pathways of
CD41 T cell activation. We interpret these data to suggest
that ECs, in addition to providing direct costimulatory sig-
nals to CD41 T cells, predominantly via LFA-3, may pro-
mote CD28-dependent trans-costimulation by the induc-
tion of CD86 on CD41 T cells. The ability of ECs to
modify leukocytes for provision of trans-costimulatory sig-
nals probably provides an additional mechanism whereby
ECs regulate inflammatory responses.
Although PHA-activated CD41 T cells have been re-
ported previously to express both CD80 and CD86, the
functional importance of CD41 T cell expression of these
molecules is controversial. Azuma et al. have shown that
CD41 T cell clones expressing CD80 are able to stimulate
T cell cytokine production and proliferation in a mixed
lymphocyte reaction (33). Furthermore, Jeannin et al. re-
ported that human effector T cells express CD86, and may
costimulate naive T cell responses (34). In contrast, it has
been reported that CD41 T cell CD86 may be nonfunc-
tional due to reduced posttranslational glycosylation (40).
Our studies clearly demonstrate that CD41 T cell CD86 is
functional and may provide CD28-mediated costimulatory
signals in trans to autologous T cells when signal one is
provided by mitogen or alloantigen on ECs. The high pu-
rity of our CD41 T cell preparations and the high expres-
sion of CD86 on CD41 T cells after coculture with ECs
suggests that CD86-mediated costimulation was provided
by CD41 T cells and not low numbers of contaminating
CD861 dendritic cells. To confirm this, we depleted our
CD41 T cell population of HLA-DR– and CD14-express-
ing cells to eliminate contaminating CD41 APCs (36). The
resulting highly purified CD41 T cells proliferated to IFN-
g–treated ECs, expressed enhanced levels of CD86 after 72 h
Figure 8. Functional effects of resting and EC-
modified monocytes. (A) Monocytes were cultured
on a monolayer of IFN-g–treated ECs or a plastic
culture dish as a control for 72 h and were reiso-
lated by positive selection using CD14-coated
magnetic beads. Monocytes were then irradiated
(1,750 rads) and added at fixed ratios to either allo-
geneic or autologous CD41 T cells (105) for 6 d.
(B) Resting or EC-modified monocytes (as above)
were cocultured with allogeneic CD41 T cells in a
mixed leukocyte reaction (stimulator/responder ra-
tio 1:10). Anti–HLA-DR (10 mg/ml) or CTLA4 Ig
(10  mg/ml) were added to cultures. Proliferation
was assessed by [3H]thymidine incorporation after 6 d
of coculture. Results shown are representative of
three experiments in triplicate cultures 6 1 SD.564 ECs Modify the Costimulatory Capacity of Transmigrating Leukocytes
coculture with IFN-g–treated ECs and provide functional
T cell–T cell trans-costimulation. We note that EC stimu-
lation of CD41 T cells resulted in a discrete population of
CD86 expressing CD41 T cells; which may represent allo-
activated CD41 T cells. Although resting CD41 T cells
may express low levels of CD86, we suggest that this level
is insufficient to provide effective costimulation. Indeed,
anti-CD86 reagents fail to inhibit CD41 T cell activation
when signal one is provided by mitogen and costimulation
is dependent on constitutive cell surface molecules ex-
pressed on ECs or resting CD41 T cells (15, 39).
EC induction of CD41 T cell CD86 is mediated in part
by stimulation of the TCR and T cell CD2. Anti–class II
MHC mAbs and anti–LFA-3 mAbs inhibit the ability of
ECs to modify CD41 T cells to provide CD86-mediated
costimulation. Consistent with these findings, we found by
FACS® analysis that LFA-3 fusion protein and low doses of
PHA additively promote CD86 protein expression in puri-
fied CD41 T cells (data not shown). Therefore, EC LFA-3
may provide costimulation to CD41 T cells via two dis-
tinct mechanisms. First, LFA-3 may directly costimulate
cytokine production and CD41 T cell proliferation via in-
teractions in cis (35); and second, LFA-3 may promote
trans-costimulation via the induction of CD86 on T cells.
Although CD40 signals induce CD80 and CD86 expres-
sion on B cells (41), monocytes, and dendritic cells (42), we
find that interruption of CD40L–CD40 interactions does
not inhibit EC induction of functional CD41 T cell CD86.
This is consistent with the low levels of CD40 expression
on resting and activated CD41 T cells. Similarly, OX40L-
OX40 interactions do not appear to be functional in EC
induction of CD86 expression by CD41 T cells. Consistent
with these observations, neither anti-CD40 mAbs nor anti-
CD40L mAbs inhibit alloactivation of CD41 T cells by
IFN-g–treated ECs (data not shown).
Our findings that allogeneic ECs can fully activate bulk
populations of CD41 T cells are similar to those reported
by other groups (13, 15, 35, 43). However, they are differ-
ent from those reported by Marelli-Berg et al., in which
ECs were found to have limited costimulatory function
(16). A common finding of all groups is that addition of
B7-dependent costimulation in trans reconstitutes the abil-
ity of ECs to fully activate T cells, including naive CD41 T
cells (16, 21). We now report that CD28–CD86 interac-
tions are functional in EC-induced CD41 T cell activation,
via induction of functional CD86 on CD41 T cells.
Although B7-mediated costimulation is required for in-
duction of primary immune responses, our studies have not
specifically addressed whether ECs can activate naive
CD41 T cell populations. Previous reports have shown that
human ECs fail to activate naive (CD45RA) CD41 T cells
(15, 16), which would seem contradictory to our demon-
stration of functional CD86 on EC-modified CD41 T
cells. It is possible that the levels of CD86 expressed by
EC-modified CD41 T cells is insufficient to activate naive
CD41 T cells. Alternatively, ECs may be unable to induce
CD86 expression and thus to promote trans-costimulation
in pure populations of naive CD41 T cells (10).
Endothelial cell modification of leukocytes for subse-
quent alloantigen-dependent activation may be of great
physiologic importance for allograft rejection. We have re-
cently shown that ECs enhance the ability of CD41 T cells
to respond to intragraft cytokines including IL-2, IL-4 and
IL-12 via induction of the respective cytokine receptor (39
and our unpublished observations). Therefore, ECs may
indirectly influence the differentiation of CD41 T cells
within the graft. In addition, these studies show that ECs
may enhance the expression of costimulatory cytokines and
cell surface molecules by transmigrating leukocytes and
promote alloactivation of T cells within the allograft. Al-
though antigen-specific T cell activation is considered to
occur predominantly in primary lymphoid tissue, recent
studies have established a requirement for B7 costimulatory
signals at sites of inflammation (26). We suggest that in
vivo, EC-modified leukocytes provide B7-dependent co-
stimulation in trans, allowing for local activation of CD41
T cells via the direct pathway of allorecognition.
By enhancing the antigen presenting and costimulatory
capacity of transmigrating monocytes, ECs may promote
CD41 T cell activation through the indirect pathway of al-
lorecognition. Indeed, recent studies have demonstrated
that ECs may promote monocyte differentiation into den-
dritic cells, which may subsequently emigrate back to
lymph nodes as efficient APCs (37, 38). In support of a role
for ECs in promoting indirect allorecognition, Vallee et al.
demonstrated that indirect presentation of xenoantigens by
human APCs is crucial in the proliferative response of hu-
man CD41 T cells to porcine endothelial cells (44). We
find that EC-modified monocytes promote greater prolif-
eration of CD41 T cells than do resting monocytes. This
data is consistent with the ability of ECs to modify mono-
cytes for enhanced antigen presenting and costimulatory
function. Furthermore, the ability of EC-modified mono-
cytes to promote proliferation of autologous CD41 T cells
may suggest that ECs donate alloantigen to monocytes for
indirect activation of CD41 T cells.
In summary, we show that CD28–B7 interactions are
functional in the antigen-specific alloactivation of CD41 T
cells by ECs. Moreover by inducing CD86 and cytokine
expression, human ECs modify the costimulatory capacity
of infiltrating CD41 T cells and monocytes, which may
provide costimulation in trans to CD41 T cells. Our new
findings provide evidence for a unique function of the en-
dothelium in allograft rejection in the direct activation of
CD41 T cells. In addition, the modification of monocytes
by ECs may provide a mechanism whereby ECs promote
indirect allorecognition.565 Denton et al.
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